Search

Implantable Port-a-Cath System Insertion in Patients with Metastatic Colon Cancer Receiving Bevacizumab-Based Chemotherapy Combination of bevacizumab with continuous 5- fluoracil (5-FU)-based regimens are considered to be the backbone of colorectal cancer (CRC) systemic therapy. Administration of these continuous intravenous regimens requires insertion of an indwelling central venous catheters and implantable port systems. Certain aspects of the toxicity profile of Bevacizumab could interfere with implantable port-a-cath insertion. The aim of present study was to evaluate the safety port-a-cath insertion shortly before or during bevacizumab treatment in patients with metastatic colon cancer.

Metastatic Rhabdoid Melanoma of Parotid Gland: Remarkable Response to Paclitaxel/Carboplatin Combination Melanoma with rhabdoid features is an uncommon variant of malignant melanoma. We report the first case of melanoma with rhabdoid features arising from parotid gland. A 67-year-old, white male presented with a solid, mildly tender, nodular mass in the right parotid gland, with extension posterior to the auricle with ipsilateral complete facial nerve palsy. A diagnosis of rhabdoid melanoma was made based on clinical, radiological and biopsy findings. The patient underwent a radical parotidectomy with a radical neck dissection following by adjuvant radiotherapy.